Chae SY - Search Results

1

Inhibition of notch signalling ameliorates experimental inflammatory arthritis.

Park JS, Kim SH, Kim K, Jin CH, Choi KY, Jang J, Choi Y, Gwon AR, Baik SH, Yun UJ, Chae SY, Lee S, Kang YM, Lee KC, Arumugam TV, Mattson MP, Park JH, Jo DG. Park JS, et al. Among authors: chae sy. Ann Rheum Dis. 2015 Jan;74(1):267-74. doi: 10.1136/annrheumdis-2013-203467. Epub 2013 Nov 19. Ann Rheum Dis. 2015. PMID: 24255545

2

Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis.

Jin CH, Chae SY, Kim TH, Yang HK, Lee EY, Song YW, Jo DG, Lee KC. Jin CH, et al. Among authors: chae sy. J Pharmacol Exp Ther. 2010 Mar;332(3):858-65. doi: 10.1124/jpet.109.159517. Epub 2009 Nov 20. J Pharmacol Exp Ther. 2010. PMID: 19933369

3

Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.

Kim YJ, Chae SY, Jin CH, Sivasubramanian M, Son S, Choi KY, Jo DG, Kim K, Chan Kwon I, Lee KC, Park JH. Kim YJ, et al. Among authors: chae sy. Biomaterials. 2010 Dec;31(34):9057-64. doi: 10.1016/j.biomaterials.2010.08.015. Biomaterials. 2010. PMID: 20813405

4

Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.

Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, Youn YS, Kim K, Jo DG, Kwon IC, Chen X, Lee KC. Chae SY, et al. Mol Cancer Ther. 2010 Jun;9(6):1719-29. doi: 10.1158/1535-7163.MCT-09-1076. Epub 2010 Jun 1. Mol Cancer Ther. 2010. PMID: 20515949 Free PMC article.

5

Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.

Chae SY, Chun YG, Lee S, Jin CH, Lee ES, Lee KC, Youn YS. Chae SY, et al. J Pharm Sci. 2009 Apr;98(4):1556-67. doi: 10.1002/jps.21532. J Pharm Sci. 2009. PMID: 18704955

6

Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Youn YS, Shin MJ, Chae SY, Jin CH, Kim TH, Lee KC. Youn YS, et al. Among authors: chae sy. Biotechnol Lett. 2007 May;29(5):713-21. doi: 10.1007/s10529-006-9300-7. Epub 2007 Feb 23. Biotechnol Lett. 2007. PMID: 17318333

7

Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.

Youn YS, Chae SY, Lee S, Kwon MJ, Shin HJ, Lee KC. Youn YS, et al. Among authors: chae sy. Eur J Pharm Biopharm. 2008 Mar;68(3):667-75. doi: 10.1016/j.ejpb.2007.07.009. Epub 2007 Aug 2. Eur J Pharm Biopharm. 2008. PMID: 17904340

8

Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.

Chae SY, Jin CH, Shin HJ, Youn YS, Lee S, Lee KC. Chae SY, et al. Bioconjug Chem. 2008 Jan;19(1):334-41. doi: 10.1021/bc700292v. Epub 2007 Dec 14. Bioconjug Chem. 2008. PMID: 18078308

9

Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.

Lee KC, Chae SY, Kim TH, Lee S, Lee ES, Youn YS. Lee KC, et al. Among authors: chae sy. Regul Pept. 2009 Jan 8;152(1-3):101-7. doi: 10.1016/j.regpep.2008.09.008. Epub 2008 Oct 14. Regul Pept. 2009. PMID: 18951927

10

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC. Jin CH, et al. Among authors: chae sy. J Control Release. 2009 Feb 10;133(3):172-7. doi: 10.1016/j.jconrel.2008.09.091. Epub 2008 Oct 21. J Control Release. 2009. PMID: 18977255

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

164 results

Search Page